Research Grade Anti-RSV F/Fusion glycoprotein F0 (F4)

RSV是一種反式單鏈RNA病毒，共編碼11種蛋白，其中G和F表面蛋白在RSV吸附和融合過程中發(fā)揮重要作用，是產(chǎn)生中和抗體最重要的抗原位點(diǎn)，也是誘導(dǎo)機(jī)體產(chǎn)生免疫原性和抗病毒的最主要靶點(diǎn)。

(資料圖)

貨號(hào)：DVV02823

產(chǎn)品鏈接：/product/

物種反應(yīng)性：Human respiratory syncytial virus A (strain A2)

形式：Liquid

存儲(chǔ)緩沖區(qū)： PBS, pH .

濃度：1 mg/ml

純度：>95% by SDS-PAGE.

克隆性：Monoclonal

應(yīng)用：Research Grade Biosimilar

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn)：

F4/80 as a Major Macrophage Marker: The Case of the Peritoneum and Spleen. PMID: 28455709F4/80: the macrophage-specific adhesion-GPCR and its role in immunoregulation. PMID: 21618834F4/80 and the related adhesion-GPCRs. PMID: 21952799The F4 fimbrial antigen of Escherichia coli and its receptors. PMID: 10703706Receptor for the F4 fimbriae of enterotoxigenic Escherichia coli (ETEC). PMID: 25967654Methodology and application of Escherichia coli F4 and F18 encoding infection models in post-weaning pigs. PMID: 31210932F4-TCNQ on Epitaxial Bi-Layer Graphene: Concentration- and Orientation-Dependent Charge Transfer at the Interface. PMID: 36512752F4, a collagen XIX-derived peptide, inhibits tumor angiogenesis through αvβ3 and α5β1 integrin interaction. PMID: 34308743A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. PMID: 36334787分別構(gòu)建攜帶RSV-B1株F基因截短片段和全長的重組腺病毒rAd-F0DeltaTM和rAd-F0。在BALB/c小鼠中進(jìn)行的免疫原性比較研究表明，每種載體均能誘導(dǎo)產(chǎn)生與RSV-long和RSV-A2病毒交叉反應(yīng)的rsv - b1特異性抗體。抗rsv - b1抗體具有中和活性，對(duì)rsv -長株和RSV-A2分離株也具有較強(qiáng)的交叉中和活性。細(xì)胞免疫反應(yīng)分析顯示，rAd-F0DeltaTM和rAd-F0均能誘導(dǎo)Th1和Th2表型的CD4(+) t細(xì)胞應(yīng)答和F蛋白特異性ctl。rAd-F0DeltaTM和rAd-F0免疫小鼠脾細(xì)胞產(chǎn)生的Th2細(xì)胞因子(IL-4、IL-5和IL-13)明顯低于熱滅活RSV-B1 (hirv - b1)免疫小鼠。總體體液和細(xì)胞免疫應(yīng)答的比較表明，rAd-F0DeltaTM較rAd-F0具有更強(qiáng)的免疫原性。與接種hirv - b1的小鼠相比，兩種重組腺病毒載體產(chǎn)生的抗病毒免疫對(duì)RSV-B1活病毒攻擊產(chǎn)生了保護(hù)作用，原因是肺內(nèi)恢復(fù)的病毒載量較低，體重減輕的恢復(fù)速度較快，嗜酸性粒細(xì)胞計(jì)數(shù)較低。這些研究結(jié)果表明，rAd-F0DeltaTM或rAd-F0具有符合RSV候選疫苗預(yù)期要求的免疫原性。

關(guān)鍵詞：